Physician
Northeastern Health System
Northeastern Health System was paid $9.83M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoNORTHEASTERN HEALTH SYSTEM
TAHLEQUAH, OK 74464
TAHLEQUAH, OK 74464
33aNPI1003865999assigned 05/08/2006
33bProvider typeEmergency Medicine Physician
28Total paid$9.83M
24GClaims131,706
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Oklahoma
Rank by total paid#4 of 81
Median peer was paid$154K
This provider vs. median64×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,718 | $835K | |
| 2019 | 13,250 | $940K | |
| 2020 | 9,299 | $717K | |
| 2021 | 17,445 | $1.20M | |
| 2022 | 30,554 | $2.15M | |
| 2023 | 29,749 | $2.43M | |
| 2024incomplete | 14,691 | $1.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 12,303 | 12,141 | $3.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 17,145 | 16,982 | $2.84M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 2,571 | 2,539 | $891K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 7.9% | 1,041 | 581 | $772K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 1,976 | 1,947 | $266K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 1,973 | 1,954 | $169K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 3,803 | 3,769 | $144K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.2% | 27 | 27 | $117K |
| 80053 | Comprehensive metabolic panel | 1.1% | 8,262 | 7,878 | $109K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 2,888 | 2,844 | $100K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,870 | 2,829 | $88K |
| 69421 | <1% | 44 | 34 | $66K |
142 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,447 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,445 | $56K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,871 | $54K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 144 | $53K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 945 | $47K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,330 | $46K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 663 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 708 | $42K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 388 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 839 | $36K |
| 80305 | <1% | 2,817 | $30K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 667 | $29K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,735 | $28K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,967 | $27K |
| 87529 | <1% | 396 | $25K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 38 | $25K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 122 | $22K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 29 | $21K |
| 87581 | <1% | 653 | $20K | |
| 87276 | <1% | 1,474 | $20K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 648 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,470 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 327 | $18K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 67 | $17K |
| 81025 | <1% | 1,870 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 982 | $14K |
| 73560 | <1% | 595 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 238 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 958 | $11K |
| 82805 | <1% | 122 | $11K | |
| 73110 | <1% | 366 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,158 | $8K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 380 | $8K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 281 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 122 | $8K |
| 80061 | Lipid panel | <1% | 615 | $7K |
| 87511 | <1% | 243 | $7K | |
| 87481 | <1% | 215 | $6K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 173 | $6K |
| 85027 | <1% | 1,066 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 39 | $6K |
| 80055 | <1% | 127 | $6K | |
| 87486 | <1% | 653 | $6K | |
| 87070 | <1% | 634 | $5K | |
| 83615 | <1% | 1,089 | $5K | |
| 43235 | <1% | 15 | $5K | |
| 86803 | <1% | 391 | $5K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 20 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 95 | $5K |
| 84484 | <1% | 439 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 163 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 55 | $5K |
| 81003 | <1% | 1,976 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 25 | $4K |
| 87275 | <1% | 325 | $4K | |
| 73562 | <1% | 206 | $4K | |
| 86787 | <1% | 305 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 415 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 147 | $4K |
| 81001 | <1% | 1,237 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $3K |
| 83690 | <1% | 568 | $3K | |
| 86592 | <1% | 847 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 77 | $3K |
| 76801 | <1% | 45 | $3K | |
| 73030 | <1% | 160 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 37 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 300 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $2K |
| 73130 | <1% | 109 | $2K | |
| 86762 | <1% | 167 | $2K | |
| 82951 | <1% | 190 | $2K | |
| 84702 | <1% | 139 | $2K | |
| 87807 | <1% | 152 | $2K | |
| 83735 | <1% | 289 | $2K | |
| 81002 | <1% | 602 | $2K | |
| 86850 | <1% | 189 | $2K | |
| 86756 | <1% | 114 | $2K | |
| 86235 | <1% | 16 | $1K | |
| 84439 | <1% | 145 | $1K | |
| 87430 | <1% | 67 | $927.18 | |
| 86901 | <1% | 302 | $763.67 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $744.60 |
| 86900 | <1% | 299 | $741.44 | |
| 86480 | <1% | 12 | $618.32 | |
| 73610 | <1% | 30 | $616.36 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 54 | $581.11 |
| 88300 | <1% | 57 | $562.31 | |
| 84403 | <1% | 24 | $547.34 | |
| 82677 | <1% | 25 | $491.00 | |
| 84481 | <1% | 28 | $481.88 | |
| 84134 | <1% | 30 | $389.40 | |
| 83718 | <1% | 54 | $385.84 | |
| 82105 | <1% | 25 | $340.60 | |
| 86160 | <1% | 15 | $330.77 | |
| 86336 | <1% | 25 | $316.40 | |
| 82681 | <1% | 12 | $298.20 | |
| 82670 | <1% | 12 | $298.20 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 731 | $278.24 |
| 82550 | <1% | 50 | $277.92 | |
| 83520 | <1% | 16 | $276.48 | |
| 84478 | <1% | 54 | $275.12 | |
| 84402 | <1% | 12 | $271.92 | |
| 72100 | <1% | 12 | $270.68 | |
| 73630 | <1% | 15 | $255.25 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 183 | $246.42 |
| 84144 | <1% | 13 | $237.15 | |
| 94664 | <1% | 16 | $224.64 | |
| 83516 | <1% | 15 | $215.46 | |
| 83001 | <1% | 13 | $214.89 | |
| 82465 | <1% | 54 | $205.11 | |
| 87210 | <1% | 41 | $194.07 | |
| 82785 | <1% | 13 | $186.32 | |
| 86200 | <1% | 16 | $184.32 | |
| 86225 | <1% | 15 | $183.30 | |
| 74018 | <1% | 13 | $181.74 | |
| 82950 | <1% | 41 | $178.34 | |
| 86038 | <1% | 15 | $161.25 | |
| 86780 | <1% | 12 | $153.14 | |
| 86140 | <1% | 31 | $142.91 | |
| 87340 | <1% | 12 | $110.28 | |
| 84460 | <1% | 18 | $84.78 | |
| 84450 | <1% | 18 | $82.98 | |
| 82565 | <1% | 18 | $81.90 | |
| 86431 | <1% | 15 | $75.60 | |
| 84550 | <1% | 14 | $56.28 | |
| 85014 | <1% | 13 | $34.72 | |
| 85018 | <1% | 13 | $34.72 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 14 | $34.00 |
| 85652 | <1% | 14 | $33.60 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 54 | $2.64 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,586 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 152 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 93 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 12 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 386 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 231 | $0.00 |
| 36000 | 0% | 97 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 197 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 216 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOODLIFF, BRIAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Northeastern Health System | Tahlequah, OK | $2.28M |
| Northeastern Health System | Tahlequah, OK | $2.09M |
| Northeastern Health System | Tahlequah, OK | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.